Inhibitor Therapeutics (INTI) 10-K2018 FY Annual report

Filed: 7 Mar 19, 9:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abstract, acute, aimed, Alice, AML, analogue, analyzing, andMayo, appraisal, attacked, attacking, atypical, Barett, benign, biochemical, boost, BRAF, cancerand, checkpoint, classified, client, CLS, Club, COD, colorectal, component, Connecticut, credited, cutoff, cytarabine, Daurismo, destroy, developmental, docetaxel, doublet, enhancement, Epalex, Erivedge, experienced, Fellow, frail, gladegib, glasdegib, grow, growing, hope, hyperplasia, immune, includeAssociation, increment, indirect, infusion, instructed, intraepithelial, inventive, isan, Kennedy, Keytruda, kinase, learned, lessee, leukemia, Linnean, live, liver, London, lump, LUNGevity, marker, maximum, melanoma, Merck, myeloid, Myriad, NCI, neck, NEJM, neoplasia, newer, notification, notified, notify, Odomzo, ofRegulation, older, Pathology, pembrolizumab, Pennside, pharmacokinetic, phenomena, placebo, potent, precision, prednisone, preemptive, prophylactic, prorated, reciting, regimen, regular, relocation, renal, replicate, scaffold, SEER, seventy, shorter, shrink, Specicare, subordinate, suggest, Supreme, tied, timeframe, toa, true, tyrosine, UConn, undergone, uplisting, useall, USPTO, vacancy, women, Yr

Removed: Abgenix, accredited, allocated, alternated, Ann, Ave, begun, bioavailable, Bioscience, BMC, calling, Cisplatin, cleared, consultant, consummated, cure, DC, disability, distributing, easily, endure, floor, forward, fulfill, great, handle, importation, importing, individualized, insolvency, IntraImmune, JDC, Lutz, Melissa, NE, NMCRPC, opened, placement, prepaid, programming, prohibited, provision, renew, reoccur, returning, Room, shortfall, step, structure, studying, terminable, testosterone, therewith, unit, upfront

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

INTI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(18 U.S.C. 1350)

Pursuant to Section 906 of the Sarbanes-Oxley Act of (18 U.S.C. 1350), the undersigned officer of HedgePath Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to the best of such officer’s knowledge and belief, that:

(1) The Annual Report on Form10-K for the year ended December 31, 2018 (the “Form10-K”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Form10-K fairly presents, in all materials respects, the financial condition and results of operations of the Company.


Date: March 7, 2019				/s/ Nicholas J. Virca
				Nicholas J. Virca, President and Chief Executive Officer

This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Securities Exchange Act.